Form 4: Sera Prognostics Director Gregory Critchfield Reports Stock and Option Awards

Sentiment:

SEC Form 4 Filing


Director Gregory Critchfield of Sera Prognostics reports the acquisition of restricted stock units and stock options, both vesting monthly over one year.

Summary

  • On June 6, 2024, Gregory Critchfield, a director of Sera Prognostics, Inc., was granted 7,117 restricted stock units (RSUs) and 10,549 stock options.
  • The RSUs and stock options vest monthly over one year, starting June 6, 2024, contingent upon Critchfield's continued service to the company.
  • The exercise price for the stock options is $8.43.
  • Following these transactions, Critchfield beneficially owns 807,270 shares of Class A Common Stock and 10,549 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard equity grant to a director. It's a positive for the director but doesn't necessarily indicate a significant shift in the company's prospects.

Positives

  • The grant of RSUs and stock options aligns the director's interests with those of the shareholders, incentivizing continued service and performance.
  • The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of equity awards suggests an expectation of continued service from the director.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry to attract and retain talent.

Comparison to Industry Standards

  • Equity compensation for directors in biotech companies typically includes a mix of stock options and restricted stock units.
  • Vesting schedules of one to four years are common to ensure long-term alignment with company performance.
  • The specific amounts and terms of the awards would need to be compared to peer companies of similar size and stage of development to assess competitiveness.

Stakeholder Impact

  • Shareholders may view the equity grants as a way to align management's interests with theirs.
  • Employees may see this as part of the overall compensation structure at the company.

Key Dates

DateDescription
06/06/2024Date of transaction: Grant of RSUs and stock options.
06/06/2024Vesting commencement date for RSUs and stock options.
06/06/2034Expiration date for stock options.
06/07/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.